Cancer/testis genes in multiple myeloma: Expression patterns and prognosis value determined by microarray analysis

Journal of Immunology

Volumn 178, Issue 5, 2007, Pages 3307-3315

  Condomines, Maud ^a,b,c   Hose, Dirk ^d   Raynaud, Pierre ^a,c   Hundemer, Michael ^d   De Vos, John ^a,b,c   Baudard, Marion ^a   Moehler, Thomas ^d   Pantesco, Véronique ^a,b   Moos, Marion ^d   Schved, Jean François ^a,c   Rossi, Jean François ^a,c   Rème, Thierry ^a,b   Goldschmidt, Hartmut ^d,e   Klein, Bernard ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN;

ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CONTROLLED STUDY; DDX43 GENE; DISEASE FREE SURVIVAL; GAGE 1 8 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; KM HN 1 GENE; MAGE A3 6 12 GENE; MAGE A5 GENE; MAGE C1 GENE; MAGE C2 GENE; MICROARRAY ANALYSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MORC GENE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; SPACA3 GENE; SSX 4 GENE; X CHROMOSOME;

EID: 33847377240     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.5.3307     Document Type: Article

References (62)

1. Barlogie, B., J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley. 2004. Treatment of multiple myeloma. Blood 103: 20-32.
2. Bakkus, M. H., Y. Bouko, D. Samson, J. F. Apperley, K. Thielemans, B. Van Camp, A. Benner, H. Goldschmidt, M. Moos, and F. W. Cremer. 2004. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br. J. Haematol. 126: 665-674.
3. Tarte, K., X. G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J. F. Rossi, and B. Klein. 1999. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. J. Immunol. 163: 514-524.
4. Pellat-Deceunynck, C., G. Jego, J. L. Harousseau, H. Vie, and R. Bataille. 1999. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells. Clin. Cancer Res. 5: 705-709.
5. Dhodapkar, M. V., J. Krasovsky, and K. Olson. 2002. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 99: 13009-13013.
6. Noonan, K., W. Matsui, P. Serafini, R. Carbley, G. Tan, J. Khalili, M. Bonyhadi, H. Levitsky, K. Whartenby, and I. Borrello. 2005. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 65: 2026-2034.
7. Tricot, G., D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi, and B. Barlogie. 1996. Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198.
8. Maloney, D. G., A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, et al. 2003. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102: 3447-3454.
9. Kroger, N., A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov, H. Schieder, H. Renges, B. Fehse, T. Zabelina, A. Nagler, and A. R. Zander. 2004. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 104: 3361-3363.
10. Reichardt, V. L., C. Milazzo, W. Brugger, H. Einsele, L. Kanz, and P. Brossart 2003. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88: 1139-1149.
11. Yi, Q. 2003. Dendritic cell-based immunotherapy in multiple myeloma. Leuk. Lymphoma 44: 2031-2038.
12. Coscia, M., S. Mariani, S. Battaglio, C. Di Bello, F. Fiore, M. Foglietta, A. Pileri, M. Boccadoro, and M. Massaia. 2004. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18: 139-145.
13. Hurvitz, S. A., and J. M. Timmerman. 2005. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 17: 432-440.
14. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26: 2671-2679.
15. Van den Eynde, B. J., and T. Boon. 1997. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res. 27: 81-86.
16. Van Der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van Den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188: 51-64.
17. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11: 263-270.
18. Simpson, A. J., O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5: 615-625.
19. Scanlan, M. J., A. J. Simpson, and L. J. Old. 2004. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4: 1.
20. Wang, Z., Y. Zhang, A. Mandal, J. Zhang, F. J. Giles, J. C. Herr, and S. H. Lim. 2004. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin. Cancer Res. 10: 6544-6550.
21. Monji, M., T. Nakatsura, S. Senju, Y. Yoshitake, M. Sawatsubashi, M. Shinohara, T. Kageshita, T. Ono, A. Inokuchi, and Y. Nishimura. 2004. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin. Cancer Res. 10: 6047-6057.
22. Chen, Y. T., M. J. Scanlan, C. A. Venditti, R. Chua, G. Theiler, B. J. Stevenson, C. Iseli, A. O. Gure, T. Vasicek, R. L. Strausberg, et al. 2005. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc. Natl. Acad. Sci. USA 102: 7940-7945.
23. van Baren, N., M. C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V. G. Brichard, et al. 2005. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23: 9008-9021.
24. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179: 921-930.
25. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698.
26. Stockert, E., E. Jager, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187: 1349-1354.
27. Korangy, F., L. A. Ormandy, J. S. Bleck, J. Klempnauer, L. Wilkens, M. P. Manns, and T. F. Greten. 2004. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10: 4332-4341.
28. + T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 106: 4217-4224.
29. Tarte, K., F. Zhan, J. De Vos, B. Klein, and J. Shaughnessy, Jr. 2003. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 102: 592-600.
30. Mattioli, M., L. Agnelli, S. Fabris, L. Baldini, F. Morabito, S. Bicciato, D. Verdelli, D. Intini, L. Nobili, L. Cro, et al. 2005. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24: 2461-2473.
31. van Rhee, F., S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, and G. Tricot. 2005. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105: 3939-3944.
32. Jungbluth, A. A., S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y. T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, and H. J. Cho. 2005. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106: 167-174.
33. Zhang, X. G., J. P. Gaillard, N. Robillard, Z. Y. Lu, Z. J. Gu, M. Jourdan, J. M. Boiron, R. Bataille, and B. Klein. 1994. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654-3663.
34. Rebouissou, C., J. Wijdenes, P. Autissier, K. Tarte, V. Costes, J. Liautard, J. F. Rossi, J. Brochier, and B. Klein. 1998. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91: 4727-4737.
35. Gu, Z. J., J. De Vos, C. Rebouissou, M. Jourdan, X. G. Zhang, J. F. Rossi, J. Wijdenes, and B. Klein. 2000. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 14: 188-197.
36. Tarte, K., J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J. F. Rossi, J. Shaughnessy, Jr., et al. 2002. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100: 1113-1122.
37. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95: 14863-14868.
38. Su, A. I., T. Wiltshire, S. Batalov, H. Lapp, K. A. Ching, D. Block, J. Zhang, R. Soden, M. Hayakawa, G. Kreiman, et al. 2004. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101: 6062-6067.
39. Moreaux, J., E. Legouffe, E. Jourdan, P. Quittet, T. Reme, C. Lugagne, P. Moine, J. F. Rossi, B. Klein, and K. Tarte. 2004. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103: 3148-3157.
40. Dhodapkar, M. V., K. Osman, J. Teruya-Feldstein, D. Filippa, C. V. Hedvat, K. Iversen, D. Kolb, M. D. Geller, H. Hassoun, T. Kewalramani, et al. 2003. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 3: 9.
41. van Baren, N., F. Brasseur, D. Godelaine, G. Harnes, A. Ferrant, F. Lehmann, M. Andre, C. Ravoet, C. Doyen, G. C. Spagnoli, et al. 1999. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94: 1156-1164.
42. Pellat-Deceunynck, C. 2003. Tumour-associated antigens in multiple myeloma. Br. J. Haematol. 120: 3-9.
43. Wang, Z., Y. Zhang, H. Liu, E. Salati, M. Chiriva-Internati, and S. H. Lim. 2003. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 101: 955-960.
44. Taylor, B. J., T. Reiman, J. A. Pittman, J. J. Keats, D. R. de Bruijn, M. J. Mant, A. R. Belch, and L. M. Pilarski. 2005. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J. Immunother. 28: 564-575.
45. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al. 1998. Simultaneous humoral and cellular immune response against cancer-iestis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
46. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60: 4499-4506.
47. Chiriva-Internati, M., Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S. H. Lim. 2002. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 100: 961-965.
48. Kyle, R. A., T. M. Therneau, S. V. Rajkumar, J. R. Offord, D. R. Larson, M. F. Plevak, and L. J. Melton III. 2002. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346: 564-569.
49. Dhodapkar, M. V., J. Krasovsky, K. Osman, and M. D. Geller. 2003. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J. Exp. Med. 198: 1753-1757.
50. Baylin, S. B., and J. G. Herman. 2000. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16: 168-174.
51. Wischnewski, F., K. Pantel, and H. Schwarzenbach. 2006. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 4: 339-349.
52. Gure, A. O., R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J. Simpson, Y. T. Chen, L. J. Old, and N. K. Altorki. 2005. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11: 8055-8062.
53. Yoshida, N., H. Abe, T. Ohkuri, D. Wakita, M. Sato, D. Noguchi, M. Miyamoto, T. Morikawa, S. Kondo, H. Ikeda, and T. Nishimura. 2006. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int. J. Oncol. 28: 1089-1098.
54. Kim, J., H. A. Reber, O. J. Hines, K. K. Kazanjian, A. Tran, X. Ye, F. F. Amersi, S. R. Martinez, S. M. Dry, A. J. Bilchik, and D. S. Hoon. 2006. The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer. 118:2269-2275.
55. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
56. + T cells. J. Exp. Med. 202: 907-912.
57. Rapoport, A. P., E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11: 1230-1237.
58. Cho, H. J., L. Farol, J. L. Truong, W. R. Austin, Y.-T. Chen, N. Bhardwaj, R. Niesvizky, L. T. Old, and S. Chen-Kiang. 2005. CT7 (MAGE-C1)-Specific cellular immune responses in the bone marrow microenvironment of multiple myeloma patients. Blood 106: 108A (Abstr.).
59. Atanackovic, D., J. Arfsten, Y. Cao, S. Gnjatic, F. Schnieders, K. Bartels, G. Schilling, C. Faltz, C. Wolschke, J. Dierlamm, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood In press.
60. Condomines, M., P. Quittet, Z. Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J. F. Schved, et al. 2006. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J. Immunol. 176: 6631-6639.
61. Choi, C., M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, and P. Beckhove. 2005. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105: 2132-2134.
62. Hundemer, M., S. Schmidt, M. Condomines, A. Lupu, D. Hose, M. Moos, F. Cremer, C. Kleist, P. Terness, S. Belle, et al. 2006. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp. Hematol. 34: 486-496.